相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Complex immune correlates of protection in HIV-1 vaccine efficacy trials
Georgia D. Tomaras et al.
IMMUNOLOGICAL REVIEWS (2017)
Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments
Peter Hraber et al.
JOURNAL OF VIROLOGY (2017)
Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner
Thomas Musich et al.
JOURNAL OF VIROLOGY (2017)
Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design
Jason Gorman et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2016)
Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design
Jason Gorman et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2016)
HIV-Host Interactions: Implications for Vaccine Design
Barton F. Haynes et al.
CELL HOST & MICROBE (2016)
Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits
Xunqing Jiang et al.
JOURNAL OF VIROLOGY (2016)
Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response
Susan Zolla-Pazner et al.
JOURNAL OF VIROLOGY (2016)
Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens
Benedikt Asbach et al.
JOURNAL OF VIROLOGY (2016)
Approaches to preventative and therapeutic HIV vaccines
Glenda E. Gray et al.
CURRENT OPINION IN VIROLOGY (2016)
Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein
Jianhui Tian et al.
PLOS COMPUTATIONAL BIOLOGY (2016)
Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization
Cecilia Rademeyer et al.
PLOS PATHOGENS (2016)
Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses
Matthew Zirui Tay et al.
PLOS PATHOGENS (2016)
Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology
Amy W. Chung et al.
CELL (2015)
Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates
Xiaoying Shen et al.
JOURNAL OF VIROLOGY (2015)
Immune correlates of vaccine protection against HIV-1 acquisition
Lawrence Corey et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies
Allan deCamp et al.
JOURNAL OF VIROLOGY (2014)
HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities
Justin Pollara et al.
JOURNAL OF VIROLOGY (2014)
Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection
Susan Zolla-Pazner et al.
PLOS ONE (2014)
Antibody persistence and T-cell balance: Two key factors confronting HIV vaccine development
George K. Lewis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines
Amy W. Chung et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination
Nicole L. Yates et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Epitope target structures of Fc-mediated effector function during HIV-1 acquisition
George K. Lewis et al.
CURRENT OPINION IN HIV AND AIDS (2014)
Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates
Georgia D. Tomaras et al.
VACCINES (2014)
Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2
Hua-Xin Liao et al.
IMMUNITY (2013)
Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion
S. Munir Alam et al.
JOURNAL OF VIROLOGY (2013)
Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial
Susan Zolla-Pazner et al.
PLOS ONE (2013)
Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial
Raphael Gottardo et al.
PLOS ONE (2013)
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG
Georgia D. Tomaras et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models
Miguel Lacerda et al.
VIROLOGY JOURNAL (2013)
The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120
Nicos Karasavvas et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2012)
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144
Merlin L. Robb et al.
LANCET INFECTIOUS DISEASES (2012)
B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study
Barton F. Haynes et al.
NATURE BIOTECHNOLOGY (2012)
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Barton F. Haynes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals
Miroslaw K. Gorny et al.
VIROLOGY (2012)
High-Throughput Quantitative Analysis of HIV-1 and SIV-Specific ADCC-Mediating Antibody Responses
Justin Pollara et al.
CYTOMETRY PART A (2011)
A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples
Margaret E. Ackerman et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2011)
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
Jason S. McLellan et al.
NATURE (2011)
Broad neutralization coverage of HIV by multiple highly potent antibodies
Laura M. Walker et al.
NATURE (2011)
IgG Subclass Profiles in Infected HIV Type 1 Controllers and Chronic Progressors and in Uninfected Recipients of Env Vaccines
Kaustuv Banerjee et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2010)
Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1
Marie Pancera et al.
JOURNAL OF VIROLOGY (2010)
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Supachai Rerks-Ngarm et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Laura M. Walker et al.
SCIENCE (2009)
Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia
Georgia D. Tomaras et al.
JOURNAL OF VIROLOGY (2008)
Identification and characterisation of transmitted and early founder virus envelopes in primary HIV-1 infection
Brandon F. Keele et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand
Punnee Pitisuttithum et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in southern Africa
Ming Li et al.
JOURNAL OF VIROLOGY (2006)
Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1
Miroslaw K. Gorny et al.
JOURNAL OF VIROLOGY (2006)
Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity
Robyn L. Stanfield et al.
JOURNAL OF VIROLOGY (2006)
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies
M Li et al.
JOURNAL OF VIROLOGY (2005)
The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection
A Pinter et al.
JOURNAL OF VIROLOGY (2004)
Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades
MK Gorny et al.
JOURNAL OF VIROLOGY (2002)
AIDS - Diversity considerations in HIV-1 vaccine selection
B Gaschen et al.
SCIENCE (2002)
Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes
PN Nyambi et al.
JOURNAL OF VIROLOGY (2000)
Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M
PN Nyambi et al.
JOURNAL OF VIROLOGY (2000)
Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins
MK Gorny et al.
VIROLOGY (2000)